NNOX

Company Overview — What Does Nano-X Imaging Ltd. Do?

Nano-X Imaging Ltd., a development-stage company, develops, produces, and commercializes digital X-ray source technology for the medical imaging industry worldwide. Its X-ray source is based on a novel digital MEMs semiconductor cathode. The company also develops a prototype of the Nanox.ARC, a medical imaging system incorporating its novel digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that will allow for the delivery of medical screening as a service. Nano-X Imaging Ltd. was founded in 2011 and is headquartered in Neve Ilan, Israel. Nano-X Imaging Ltd. (NNOX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Erez I. Meltzer and employs approximately 190 people. With a market capitalization of $168M, NNOX is one of the notable companies in the Healthcare sector.

Nano-X Imaging Ltd. (NNOX) Stock Rating — Reduce (April 2026)

As of April 2026, Nano-X Imaging Ltd. receives a Reduce rating with a composite score of 30.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.NNOX ranks #3,536 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Nano-X Imaging Ltd. ranks #558 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

NNOX Stock Price and 52-Week Range

Nano-X Imaging Ltd. (NNOX) currently trades at $2.30. The stock lost $0.02 (0.9%) in the most recent trading session. The 52-week high for NNOX is $6.22, which means the stock is currently trading -63.0% from its annual peak. The 52-week low is $2.11, putting the stock 9.0% above its annual trough. Recent trading volume was 557K shares, suggesting relatively thin trading activity.

Is NNOX Overvalued or Undervalued? — Valuation Analysis

Nano-X Imaging Ltd. (NNOX) carries a value factor score of 12/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.85x, versus the sector average of 2.75x. The price-to-sales ratio is 3.55x, compared to 1.66x for the average Healthcare stock.

At current multiples, Nano-X Imaging Ltd. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Nano-X Imaging Ltd. Profitability — ROE, Margins, and Quality Score

Nano-X Imaging Ltd. (NNOX) earns a quality factor score of 26/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -113.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -101.9% versus the sector average of -33.1%.

On a margin basis, Nano-X Imaging Ltd. reports gross margins of -94.0%, compared to 71.5% for the sector. The operating margin is -502.9% (sector: -66.1%). Net profit margin stands at -474.3%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

NNOX Debt, Balance Sheet, and Financial Health

Nano-X Imaging Ltd. has a debt-to-equity ratio of 2.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $3M. Cash and equivalents stand at $39M.

NNOX has a beta of 1.39, meaning it is more volatile than the broader market — a $10,000 investment in NNOX would be expected to move 39.3% more than the S&P 500 on any given day. The stability factor score for Nano-X Imaging Ltd. is 35/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Nano-X Imaging Ltd. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Nano-X Imaging Ltd. reported revenue of $11M and earnings per share (EPS) of $-0.91. Net income for the quarter was $-54M. Gross margin was -94.0%. Operating income came in at $-57M.

In FY 2024, Nano-X Imaging Ltd. reported revenue of $11M and earnings per share (EPS) of $-0.91. Net income for the quarter was $-54M. Gross margin was -94.0%. Revenue grew 13.9% year-over-year compared to FY 2023. Operating income came in at $-57M.

In FY 2023, Nano-X Imaging Ltd. reported revenue of $10M and earnings per share (EPS) of $-1.08. Net income for the quarter was $-61M. Gross margin was -66.5%. Revenue grew 15.5% year-over-year compared to FY 2022. Operating income came in at $-63M.

In FY 2022, Nano-X Imaging Ltd. reported revenue of $9M and earnings per share (EPS) of $-2.17. Net income for the quarter was $-113M. Gross margin was -80.2%. Revenue grew 557.8% year-over-year compared to FY 2021. Operating income came in at $-118M.

Over the past 7 quarters, Nano-X Imaging Ltd. has demonstrated a growth trajectory, with revenue expanding from $0 to $11M. Investors analyzing NNOX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

NNOX Dividend Yield and Income Analysis

Nano-X Imaging Ltd. (NNOX) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

NNOX Momentum and Technical Analysis Profile

Nano-X Imaging Ltd. (NNOX) has a momentum factor score of 27/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 60/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 50/100 reflects moderate short selling activity.

NNOX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Nano-X Imaging Ltd. (NNOX) ranks #558 out of 838 stocks based on the Blank Capital composite score. This places NNOX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing NNOX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NNOX vs S&P 500 (SPY) comparison to assess how Nano-X Imaging Ltd. stacks up against the broader market across all factor dimensions.

NNOX Next Earnings Date

No upcoming earnings date has been announced for Nano-X Imaging Ltd. (NNOX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy NNOX? — Investment Thesis Summary

The quantitative profile for Nano-X Imaging Ltd. suggests caution. The quality score of 26/100 flags below-average profitability. The value score of 12/100 indicates premium valuation. Momentum is weak at 27/100, a headwind for near-term performance. High volatility (stability score 35/100) increases portfolio risk.

In summary, Nano-X Imaging Ltd. (NNOX) earns a Reduce rating with a composite score of 30.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NNOX stock.

Related Resources for NNOX Investors

Explore more research and tools: NNOX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NNOX head-to-head with peers: NNOX vs AZN, NNOX vs SLGL, NNOX vs VMD.